Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$312.47 USD

312.47
1,973,664

-2.25 (-0.71%)

Updated May 17, 2024 04:00 PM ET

After-Market: $312.53 +0.06 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Alexion to Buy Achillion for $930M, Strengthen PNH Franchise

by Zacks Equity Research

Alexion (ALXN) will buy Achillion for $930 million to strengthen its PNH franchise.

Roche Posts Solid Sales for First 9 Months of '19, Ups View

by Zacks Equity Research

Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.

Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?

by Zacks Equity Research

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.

Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth

Amgen (AMGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $204.66, marking a +0.87% move from the previous day.

Lilly Gets FDA Approval for New Oral Tablets for Migraine

by Zacks Equity Research

Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.

Roche Announces Positive Late-Stage Data on Rituxan in PV

by Zacks Equity Research

Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.

Alexion (ALXN) Collaborates With Stealth BioTherapeutics

by Zacks Equity Research

Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.

Mark Vickery headshot

Top Research Reports for Toyota, Amgen & TJX

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor (TM), Amgen (AMGN) and The TJX Companies (TJX).

Kinjel Shah headshot

3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates

by Kinjel Shah

Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.

Amgen (AMGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed the most recent trading day at $196.69, moving +0.31% from the previous trading session.

Why Alexion is a Hot Takeover Target in the Biotech Sector

by Zacks Equity Research

Let's take a look at the factors, which make Alexion (ALXN) a hot target for a takeover amid the M&A wave in the pharma/biotech sector.

Has Amgen (AMGN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (AMGN) Outperforming Other Medical Stocks This Year?

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $192.62, marking a +1.8% move from the previous day.

Merck's Pediatric Filings for Dificid Get FDA's Priority Review

by Zacks Equity Research

The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.

Why the Earnings Surprise Streak Could Continue for Amgen (AMGN)

by Zacks Equity Research

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Top Ranked Income Stocks to Buy for October 2nd

by Zacks Equity Research

Here are three stocks with buy rank and strong income characteristics for investors to consider today, October 2nd.

Should Value Investors Buy Amgen (AMGN) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Amgen (AMGN) Stock Moves -0.23%: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed the most recent trading day at $194.94, moving -0.23% from the previous trading session.

Sweta Killa headshot

Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

by Sweta Killa

Style Box ETF report for FTCS

Medicines Company's Inclisiran Succeeds in Pivotal Studies

by Zacks Equity Research

The Medicines Company's (MDCO) PCSK9 inhibitor, inclisiran, meets primary endpoint of LDL-C reduction in the remaining two phase III studies in the ORION program. Shares up.

Incyte Treats First Patient in Phase III Vitiligo Study

by Zacks Equity Research

Incyte (INCY) treats first patient in the TRuE-V clinical program on the cream formulation of ruxolitinib for the treatment of vitiligo.

John Blank headshot

Cutting Rates 50 bps. Smart, Dumb, Not Enough?

by John Blank

Did the Fed Do the Right Thing?

Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates, licensing deals, and more.

Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent

by Zacks Equity Research

Regeneron (REGN) and Sanofi get positive CHMP recommendation for the label expansion of asthma drug Dupixent in an additional indication.